Tremeau Pharmaceuticals is a clinical stage company focused on providing non-opioid pain therapies for patients with serious rare diseases and high unmet medical need. The company’s lead development program is TRM-201 (rofecoxib) for the treatment of Hemophilic Arthropathy (HA), a serious orphan disease for which high-potency opioids are the current standard of care. Tremeau has gained feedback from the FDA on its development plans and is currently initiating Phase III start-up.
Tremeau Pharmaceuticals, Inc.
53 Main Street
Suite 202
Concord, Massachusetts 01742
6174850250